Healthcare Research | Market Insights & Strategic Analysis

  The 7 major   spinal muscular atrophy markets   reached a value of USD 3.4 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 14.3 Billion by 2035, exhibiting a growth rate (CAGR) of 13.81% during 2025-2035. Spinal Muscular Atrophy (SMA) is a unique disorder caused by the degeneration of motor neurons resulting in muscle atrophy and increased difficulty in movement. SMA mostly affects young children and infants due to the mutation of the SMN1 gene, but there are rare forms which manifest in adults. There are profound developments in the treatment for SMA, with the market having the introduction of remarkable gene therapies and effective treatment options recently. By 2025, the SMA market is projected to have refined the patient experience with improvements in precision medicine, diagnosis, and treatment. Understanding Spinal Muscular Atrophy As SMA has four distinct categories, ranging from type 1 to type 4, each has its own unique characteristic...

The 7 major  substance use disorder markets  reached a value of USD 5.3 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 7.7 Million by 2035, exhibiting a growth rate (CAGR) of 3.51% during 2025-2035. The matter of substance use disorder (SUD) in connection with respiratory health has drawn attention with the increasing rate of smoking, vaping, and opioid abuse with lung-related problems. The SUD respiratory market works on the treatment of chronic obstructive pulmonary disease (COPD), residual lung damage due to chronic smoking, and opioid-induced respiratory depression. As the year 2025 approaches, the management of patients suffering from addiction-related respiratory problems is changing with the development of new therapies, digital health solutions, and harm-reduction approaches. The Relationship of Substance Use with Respiratory Health The use of tobacco, cannabis, and opiate drugs, and other illicit drugs are associated with considerable impac...

  The 7 major   epilepsy markets  reached a value of USD 2.00 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2.70 Billion by 2035, exhibiting a growth rate (CAGR) of 2.57% during 2025-2035. With over 50 million people suffering from epilepsy across the globe, it is classified as a chronic neurological disorder due to recurrent seizures. The market for epilepsy consists of medications, surgical treatments, and advanced therapies aimed at seizure control to the improvement of quality of life for patients. Furthermore, the future of  epilepsy treatment is built around developments in drug therapies, new modulating devices, and  specialized medicine, anticipated towards 2025.   Latest Trends in the Epilepsy Market (2025) Newer Generation Anti-Seizure Medications The future in the epilepsy market is marked with focus from pharmaceutical industries shifting towards ASMs with minimal to no side effects and higher recovery rates. Ma...

The 7 major  Diffuse Large B-cell Lymphoma (DLBCL) markets  reached a value of USD 4,013.3 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 5,405.9 Million by 2035, exhibiting a growth rate (CAGR) of 2.8% during 2025-2035. for approximately 30% of all cases. It affects the lymphatic system, specifically targeting a type of white blood cell known as B-cells. It's an aggressive form of cancer, although treatable. While DLBCL is diagnosed at any age, advanced age brings along a greater probability. Numerous therapies have emerged that focus on research and treatment as of 2025, drastically enhancing survival rates. With early diagnosis, the rates are even higher.  Symptoms of Diffuse Large B-cell Lymphoma Painless swelling of lymph nodes located within the neck, groin, or armpits are some signs. Every patient may experience different symptoms so weight loss, fatigue, fever, loss of appetite, night sweats, are also relevant. In cases where the organs...

  The 7 major   hepatic cirrhosis markets   reached a value of USD 3.2 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 5.0 Billion by 2035, exhibiting a growth rate (CAGR) of 4.06% during 2025-2035. The global burden caused by cirrhosis of the liver is worrying as it can stem from more than one cause. Hepatic cirrhosis, which is the serious scarring of liver tissue owing to chronic liver disease, is considered as one of the main issues for several healthcare systems across the globe. Strikingly, the predicted figures for the cirrhosis treatment market in 2025 seem quite optimistic, primarily attributed to medical innovations coupled with transformational disease patterns.     There's no denying that liver cirrhosis as a disease has a tangible impact on human life. The post-market cirrhosis treatment for 2025 is bound to see changes attributing to the recently rising consumption of alcohol and the due increase in NAFLD owing t...

  The 7 major   bacterial conjunctivitis markets   reached a value of USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4.4 Billion by 2035, exhibiting a growth rate (CAGR) of 3.12% during 2025-2035. Bacterial conjunctivitis or ‘pink eye’ remains as one of the eye diseases with the highest incidence worldwide, with millions suffering from it each year. The global burden of conjunctivitis is undergoing significant change due to increasing antibiotic resistance and shifts in healthcare systems. By 2025, changes in treatment modalities, diagnostic methods, and preventive measures will transform global management strategies of this condition. Anticipated Changes in Diagnosis and Treatment Bacterial conjunctivitis constitutes nearly 50-75% of all infective conjunctivitis cases, with the highest rates among children and contact lens users. Increased prevalence of eye infections in underdeveloped countries and poor hygiene standards in overcrowde...

The 7 major  anaphylaxis markets  reached a value of USD 3.7 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 6.9 Billion by 2035, exhibiting a growth rate (CAGR) of 5.8% during 2025-2035. The global market for anaphylaxis is rapidly changing because risk factors, treatment options, and awareness regarding severe allergic reactions are on the rise. Anaphylaxis is a life-threatening allergic response which can affect millions of people globally. Considering the rising healthcare facilities and the growing prevalence of allergies, the market is bound to evolve significantly by 2025 in terms of patient and healthcare provider solutions. Rising Prevalence and Market Opportunities There is a noticeable rise in the prevalence of anaphylaxis, especially in children. Traditional triggers such as food allergies, bugs, and medication are still in effect, but newer ones like exercise-induced anaphylaxis are gaining traction too. This along with better health car...

  The 7 major   metastatic castration-resistant prostate cancer markets   reached a value of USD 7,275.4 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 12,840.0 Million by 2035, exhibiting a growth rate (CAGR) of 5.3% during 2025-2035. The metastatic castration-resistant prostate cancer (mCRPC) market is experiencing considerable change because new therapies are being developed for the advanced stages of prostate cancer. The pandemic increase in the population’s age and the rising incidents of prostate cancer globally suggest the mCRPC treatment landscape will further evolve significantly by 2025 owing to advancements in precision medicine tailored treatments and innovative combination therapies. Increased Disease Incidence and Lack of Effective Solutions Sustained lack of effective treatment alternatives highlight growing possibilities with mCRPC, the most advanced stage of prostate cancer that persists even after the androgen deprivation ther...

  According to the IMARC Group, the  Fanconi anemia market  reached a value of US$ 49.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 78.8 Million by 2034, exhibiting a growth rate (CAGR) of 4.38% during 2024-2034.This can be attributed to the growing use of preimplantation genetic testing, which is used to identify chromosomal abnormalities in embryos formed through in-vitro fertilization and aid in assisted reproduction to prevent the transmission of defective genes. Fanconi anemia refers to an uncommon hereditary disorder defined by bone marrow failure, increased susceptibility to cancer, and numerous physical defects. The Fanconi anemia market is expanding rapidly, owing to several key factors. Primarily, the market is driven by the rising prevalence of rare genetic disorders, increasing awareness about early diagnosis, and advancements in gene therapy. Moreover, growing investment in research and development by pharmaceutical companies an...

  The 7 major non-cystic fibrosis bronchiectasis (NCFB) markets reached a value of USD 1,661.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 6,901.9 Million by 2035, exhibiting a growth rate (CAGR) of 13.78% during 2025-2035. NCFB is a progressive lung disease where there is persistent airway dilatation that leads to mucus plugging, repeated infection, and inflammation. This would mean that unlike cystic fibrosis-associated bronchiectasis, none of the treatments available is approved explicitly for NCFB, giving rise to an appreciable unmet medical need. Significant progress was mapped out in 2024 when Insmed's brensocatib was shown effective in a Phase 3 trial. As a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor, it drastically reduced the number of pulmonary exacerbations in patients with NCFB. In light of the successful outcomes, Insmed had submitted a New Drug Application to the FDA, with a likely U.S. launch by mid-2025 Advances in diagnosti...